Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000476836 | SCV000547915 | uncertain significance | Charcot-Marie-Tooth disease type 2 | 2016-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine with valine at codon 457 of the KIF1B protein (p.Met457Val). The methionine residue is moderately conserved and there is a small physicochemical difference between methionine and valine. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a KIF1B-related disease. In summary, this variant is a novel missense change that is not predicted to affect protein function. There is no indication that it causes disease, but the available evidence is currently insufficient to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. |
| Ambry Genetics | RCV004022689 | SCV002696092 | uncertain significance | not specified | 2021-06-11 | criteria provided, single submitter | clinical testing | The p.M457V variant (also known as c.1369A>G), located in coding exon 13 of the KIF1B gene, results from an A to G substitution at nucleotide position 1369. The methionine at codon 457 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |